Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Osteoporosis prevention and treatment in elderly men—a cost-effective strategy

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Center JR et al. (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297: 387–394

    Article  CAS  Google Scholar 

  2. Center JR et al. (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353: 878–882

    Article  CAS  Google Scholar 

  3. Kaufman JM et al. (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16: 510–516

    Article  CAS  Google Scholar 

  4. Lyles KW et al. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799–1809

    Article  CAS  Google Scholar 

  5. Nguyen ND et al. (2007) Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 18: 1109–1117

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

Dr Eisman has participated in multicenter international studies, received research funding and/or served as a consultant for Amgen (consultant, advisory board, study investigator), deCode Genetics (consultant), Eli Lilly (consultant, advisory board, study investigator), GE Lunar (consultant), Merck, Sharp and Dohme (consultant, advisory board), Novartis (consultant, advisory board, study investigator), NPS Pharmaceuticals (consultant), Organon (consultant, study investigator), Roche-GSK (consultant, advisory board, study investigator), Sanofi-Aventis (consultant, advisory board), Servier (consultant, advisory board), and Wyeth Australia (consultant).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eisman, J. Osteoporosis prevention and treatment in elderly men—a cost-effective strategy. Nat Rev Endocrinol 4, 198–199 (2008). https://doi.org/10.1038/ncpendmet0753

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0753

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing